Thio-TEPA demonstrates a wide range of bioactivities and pharmacokinetic properties suggestive of its potential as a therapeutic agent. In in vivo studies, it exhibits significant antineoplastic effects, particularly against P388 leukemia and L1210 leukemia in CD2F1 male mice, with an increase in life span (ILS) of up to 141.0% and a T/C ratio of 155.0%. It has an optimal dosing of 6 mg/kg/day and showcases a therapeutic ratio of 2.75 and LD50 of 18.0 mg/kg.
The compound has shown activity in additional cancer models, including cytotoxic effects against various human tumor cell lines such as breast, renal, non-small cell lung, leukemia, melanoma, central nervous system, prostate, and colon cell lines, with IC50 values ranging from 1400.0 nM to 6970.0 nM.
Pharmacokinetically, Thio-TEPA has a total body clearance rate of 6.7 mL/min/kg and a renal clearance of 0.03 mL/min/kg in humans. It also exhibits a volume of distribution at steady state of 1.6 L/kg and a half-life of 2.7 hours.
Mechanistically, Thio-TEPA inhibits various enzymes and transporters, including human cytochrome P450 2B6, rat cytochrome P450 2B1, and human liver OATP transporters, showing varying degrees of inhibition. It also shows a high partition ratio in both human and rat cytochrome P450 2B6. Additionally, it has demonstrated inhibitory activity against human BSEP with an IC50 value greater than 135000.0 nM and antiviral activity against SARS-CoV-2 by reducing induced cytotoxicity of virus-exposed cells.
Furthermore, Thio-TEPA indicates liver toxicity in humans and moderate to severe hepatotoxicity in preclinical models. It has been associated with a drug-induced liver injury severity class index of 3.0 and various levels of specific liver toxicities.
In summary, Thio-TEPA is a multi-faceted therapeutic agent with significant antitumor, enzyme inhibition, transporter inhibition, and potential antiviral activities, along with notable pharmacokinetic and hepatotoxic profiles..
Note: Summary generated by AI. Data source: ChEMBL 